Inhibition of AIDS virus replication by acemannan in vitro

Area of Science:

• Virology
• Immunology
• Pharmacology

Background:

• Human immunodeficiency virus type 1 (HIV-1) remains a significant global health challenge.
• Acemannan (ACE-M), a beta-(1,4)-linked acetylated mannan, is explored for its potential antiviral properties.
• Understanding novel antiviral agents is crucial for developing effective HIV-1 therapies.

Purpose of the Study:

• To evaluate the in vitro antiviral activity of Acemannan (ACE-M) against HIV-1.
• To compare the efficacy of ACE-M with known antiviral compounds like Castanospermine (CAS) and azidothymidine (AZT).
• To investigate ACE-M's effect on viral cytopathic effects, syncytia formation, and HIV-1 RNA levels.

Main Methods:

• In vitro antiviral assays were conducted using various human cell lines (peripheral mononuclear, CEM-SS1, MT-2(2)).
• Acemannan (ACE-M) and control compounds (CAS, deoxymannojirimycin, swainsonine, AZT, dideoxythymidine) were tested against HIV-1 strains.
• Cell viability, viral cytopathic effect, syncytia formation, and HIV-1 RNA levels were measured to determine inhibitory concentrations (IC50).

Main Results:

• Acemannan (ACE-M) demonstrated concentration-dependent inhibition of HIV-1 cytopathic effects, particularly in CEM-SS cells infected with the RFII strain (IC50 = 45).
• ACE-M showed significant suppression of syncytia formation, with complete inhibition at 62.5 micrograms/ml.
• The antiviral efficacy of ACE-M was comparable to Castanospermine (CAS) but superior to deoxymannojirimycin and swainsonine in this in vitro model.

Conclusions:

• Acemannan (ACE-M) exhibits notable in vitro antiviral activity against HIV-1.
• ACE-M's mechanism may involve inhibiting viral replication and cell-to-cell fusion (syncytia formation).
• Further research into Acemannan (ACE-M) as a potential therapeutic agent for HIV-1 is warranted.